Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Li, Jian ^a   Liu, Zezhou ^a   Guo, Mingxing ^a   Xu, Kejia ^a   Jiang, Miao ^b   Lu, Aiping ^b,c   Gao, Xiaoyan ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

11 OCTADECADIENOIC ACID; 13 HYDROPEROXY 9; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BERBERINE; CHOLESTEROL; DOCOSATRIENOIC ACID; EICOSENOIC ACID; ICOSATRIENOIC ACID; INDICAN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; SPHINGOMYELIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FATTY LIVER; HEPATITIS; HISTOPATHOLOGY; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; MALE; METABOLOMICS; MOLECULAR BIOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; THERAPY EFFECT; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84929379953     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/897914     Document Type: Article

References (41)

1. P. Angulo, "Medical progress: nonalcoholic fatty liver disease, " The New England Journal of Medicine, vol. 346, no. 16, pp. 1221-1231, 2002.
2. P. Angulo, "Nonalcoholic fatty liver disease, " Revista de Gastroenterolog Á deMéxico, vol. 70, supplement 3, pp. 52-56, 2005.
3. J. C. Cohen, J. D. Horton, and H. H. Hobbs, "Human fatty liver disease: old questions and new insights, " Science, vol. 332, no. 6037, pp. 1519-1523, 2011.
4. Z. Wang, B. Xia, C. Ma, Z. Hu, X. Chen, and P. Cao, "Prevalence and risk factors of fatty liver disease in the Shuiguohu district of Wuhan city, central China, " Postgraduate Medical Journal, vol. 83, no. 977, pp. 192-195, 2007.
5. J.-G. Fan, J. Zhu, X.-J. Li et al., "Prevalence of and risk factors for fatty liver in a general population of Shanghai, China, " Journal of Hepatology, vol. 43, no. 3, pp. 508-514, 2005.
6. M. Hamaguchi, T. Kojima, N. Takeda et al., "The metabolic syndrome as a predictor of nonalcoholic fatty liver disease, " Annals of Internal Medicine, vol. 143, no. 10, pp. 722-728, 2005.
7. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, " Hepatology, vol. 40, no. 6, pp. 1387-1395, 2004.
8. H. Tilg and A. R. Moschen, "Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, " Hepatology, vol. 52, no. 5, pp. 1836-1846, 2010.
9. L. Pacifico, V. Nobili, C. Anania, P. Verdecchia, and C. Chiesa, "Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk, "World Journal of Gastroenterology, vol. 17, no. 26, pp. 3082-3091, 2011.
10. K. J. P. Schwenger and J. P. Allard, "Clinical approaches to nonalcoholic fatty liver disease, " World Journal of Gastroenterology, vol. 20, no. 7, pp. 1712-1723, 2014.
11. J.-C. Li, X.-F. Shen, and X.-L. Meng, "A traditional Chinese medicine JiuHuangLian (Rhizoma coptidis steamed with rice wine) reduces oxidative stress injury in type 2 diabetic rats, " Food and Chemical Toxicology, vol. 59, pp. 222-229, 2013.
12. C.-H. Chang, W.-Y. Huang, C.-H. Lai et al., "Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori, " Acta Biomaterialia, vol. 7, no. 2, pp. 593-603, 2011.
13. X. Zhang, Y. Zhao, M. Zhang et al., "Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats, " PLoS ONE, vol. 7, no. 8, Article ID e42529, 2012.
14. Y. Hu and G. E. Davies, "Berberine inhibits adipogenesis in high-fat diet-induced obesity mice, " Fitoterapia, vol. 81, no. 5, pp. 358-366, 2010.
15. W. S. Kim, Y. S. Lee, S. H. Cha et al., "Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity, " American Journal of Physiology-Endocrinology and Metabolism, vol. 296, no. 4, pp. E812-E819, 2009.
16. X. Xie, X. Meng, X. Zhou, X. Shu, and H. Kong, "Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease, " Zhongguo Zhong Yao Za Zhi, vol. 36, no. 21, pp. 3032-3035, 2011.
17. Y. Gu, Y. Zhang, X. Shi et al., "Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics, " Talanta, vol. 81, no. 3, pp. 766-772, 2010.
18. H. Zhang, J. Wei, R. Xue et al., "Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression, " Metabolism: Clinical and Experimental, vol. 59, no. 2, pp. 285-292, 2010.
19. Y. Liu, L. Zhang, H. Song, and G. Ji, "Update on berberine in nonalcoholic Fatty liver disease, " Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 308134, 8 pages, 2013.
20. X. Chang, H. Yan, J. Fei et al., "Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats, " Journal of Lipid Research, vol. 51, no. 9, pp. 2504-2515, 2010.
21. M. F. Abdelmalek, S. O. Sanderson, P. Angulo et al., "Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial, " Hepatology, vol. 50, no. 6, pp. 1818-1826, 2009.
22. J. T. Bjerrum, O. H. Nielsen, F. Hao et al., "Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology, " Journal of Proteome Research, vol. 9, no. 2, pp. 954-962, 2010.
23. J. C. Lindon, E. Holmes, M. E. Bollard, E. G. Stanley, and J. K. Nicholson, "Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis, " Biomarkers, vol. 9, no. 1, pp. 1-31, 2004.
24. D. E. Kleiner, E. M. Brunt, M. van Natta et al., "Design and validation of a histological scoring systemfor nonalcoholic fatty liver disease, " Hepatology, vol. 41, no. 6, pp. 1313-1321, 2005.
25. X. Gao, M. Guo, L. Peng et al., "UPLC Q-TOF/MS-based metabolic profiling of urine reveals the novel antipyretic mechanisms of qingkailing injection in a rat model of yeastinduced pyrexia, " Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 864747, 8 pages, 2013.
26. L.-J. Xing, L. Zhang, T. Liu, Y.-Q. Hua, P.-Y. Zheng, and G. Ji, "Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver, " European Journal of Pharmacology, vol. 668, no. 3, pp. 467-471, 2011.
27. J. Y. Zhou, S. W. Zhou, K. B. Zhang et al., "Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats, " Biological and Pharmaceutical Bulletin, vol. 31, no. 6, pp. 1169-1176, 2008.
28. Y. S. Lee, W. S. Kim, K. H. Kim et al., "Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states, " Diabetes, vol. 55, no. 8, pp. 2256-2264, 2006.
29. B. M. Arendt, D. W. Ma, B. Simons et al., "Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine, " Applied Physiology, Nutrition, andMetabolism, vol. 38, no. 3, pp. 334-340, 2013.
30. M. S. Han, Y.-M. Lim, W. Quan et al., "Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance, " Journal of Lipid Research, vol. 52, no. 6, pp. 1234-1246, 2011.
31. Z. Li, L. B. Agellon, and D. E. Vance, "A role for high density lipoproteins in hepatic phosphatidylcholine homeostasis, " Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1771, no. 7, pp. 893-900, 2007.
32. R. Testi, "Sphingomyelin breakdown and cell fate, " Trends in Biochemical Sciences, vol. 21, no. 12, pp. 468-471, 1996.
33. R. W. S. Chung, A. Kamili, S. Tandy et al., "Dietary sphingomyelin lowers hepatic lipid levels and inhibits intestinal cholesterol absorption in high-fat-fed mice, " PLoS ONE, vol. 8, no. 2, Article ID e55949, 2013.
34. P. D. Klein, "Linoleic acid and cholesterol metabolism in the rat. II. Effects of dietary cholesterol on plasma and liver ester composition, " Archives of Biochemistry and Biophysics, vol. 81, no. 2, pp. 382-389, 1959.
35. P. D. Klein, "Linoleic acid and cholesterolmetabolism in the rat. I. The effect of dietary fat and linoleic acid levels on the content and composition of cholesterol esters in liver and plasma, " Archives of Biochemistry and Biophysics, vol. 76, no. 1, pp. 56-64, 1958.
36. H. Kahleova, M. Matoulek, M. Bratova et al., "Vegetarian dietinduced increase in linoleic acid in serum phospholipids is associated with improved insulin sensitivity in subjects with type 2 diabetes, " Nutrition & Diabetes, vol. 3, article e75, 2013.
37. P. Parra, A. Palou, and F. Serra, "Moderate doses of conjugated linoleic acid reduce fat gain, maintain insulin sensitivity without impairing inflammatory adipose tissue status in mice fed a high-fat diet, " Nutrition and Metabolism, vol. 7, article 5, 2010.
38. B. Ahrén, A. Mari, C. L. Fyfe et al., "Effects of conjugated linoleic acid plus -3 polyunsaturated fatty acids on insulin secretion and estimated insulin sensitivity in men, " European Journal of Clinical Nutrition, vol. 63, no. 6, pp. 778-786, 2009.
39. F. Moloney, T.-P. Yeow, A. Mullen, J. J. Nolan, and H. M. Roche, "Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus, "The American Journal of Clinical Nutrition, vol. 80, no. 4, pp. 887-895, 2004.
40. Y. Kawashima, K. Musoh, and H. Kozuka, "Peroxisome proliferators enhance linoleic acid metabolism in rat liver. Increased biosynthesis of 6 polyunsaturated fatty acids, " Journal of Biological Chemistry, vol. 265, no. 16, pp. 9170-9175, 1990.
41. W. B. Dunn, D. Broadhurst, P. Begley et al., "Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry, " Nature Protocols, vol. 6, no. 7, pp. 1060-1083, 2011.